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Dense genotyping of immune-related susceptibility
loci reveals new insights into the genetics of
psoriatic arthritis
John Bowes1, Ashley Budu-Aggrey1,2, Ulrike Huffmeier3, Steffen Uebe3, Kathryn Steel1, Harry L. Hebert1,4,
Chris Wallace5,6, Jonathan Massey1, Ian N. Bruce1,7, James Bluett1,7, Marie Feletar8, Ann W. Morgan9,
Helena Marzo-Ortega9, Gary Donohoe10, Derek W. Morris10, Philip Helliwell9, Anthony W. Ryan11, David Kane12,
Richard B. Warren4, Eleanor Korendowych13, Gerd-Marie Alenius14, Emiliano Giardina15, Jonathan Packham16,
Ross McManus11, Oliver FitzGerald17, Neil McHugh13, Matthew A. Brown18, Pauline Ho1,7, Frank Behrens19,
Harald Burkhardt19, Andre Reis3 & Anne Barton1,2
Psoriatic arthritis (PsA) is a chronic inﬂammatory arthritis associated with psoriasis and,
despite the larger estimated heritability for PsA, the majority of genetic susceptibility loci
identiﬁed to date are shared with psoriasis. Here, we present results from a case–control
association study on 1,962 PsA patients and 8,923 controls using the Immunochip genotyping
array. We identify eight loci passing genome-wide signiﬁcance, secondary independent effects
at three loci and a distinct PsA-speciﬁc variant at the IL23R locus. We report two novel loci and
evidence of a novel PsA-speciﬁc association at chromosome 5q31. Imputation of classical HLA
alleles, amino acids and SNPs across the MHC region highlights three independent associations
to class I genes. Finally, we ﬁnd an enrichment of associated variants to markers of open
chromatin in CD8þ memory primary Tcells. This study identiﬁes key insights into the genetics
of PsA that could begin to explain fundamental differences between psoriasis and PsA.
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T
he increased prevalence of chronic inﬂammatory arthritis
among patients with psoriasis is well described and the
distinct clinical entity, referred to as psoriatic arthritis
(PsA) [OMIM 607507], is now clearly recognized1. Prevalence
rates of PsA have been estimated to be between 0.3 and 1%
(ref. 2); in a recent study, 14% of a UK cohort of psoriasis patients
also had co-existing PsA3. PsA is characterized by inﬂammation
of the distal interphalangeal joints, sacroiliac joints and entheses;
it is typically seronegative for autoantibodies and is classed as a
spondyloarthritis. Its presence leads to increased morbidity and a
lower quality of life than psoriasis alone4. The burden of illness
and the socioeconomic impact of PsA has been shown to be
comparable to patients with RA and ankylosing spondylitis and is
estimated to result in a loss to the exchequer of over d3.5 billion
per annum5–7.
Familial aggregation studies have demonstrated a strong
genetic component for both psoriasis and PsA. An elegant
genealogical study conducted in the Icelandic population
calculated the recurrence risk ratio (l1) for ﬁrst degree relatives
to be 40 for PsA8, while family studies for psoriasis estimate l1
at B8 (ref. 9). This suggests a substantial difference in the
genetic architecture of the two diseases with a heavier genetic
burden for PsA.
The majority of susceptibility loci identiﬁed to date are shared
between the two phenotypes, which is expected, and is mediated
by the presence of psoriasis in both traits. The large degree of
overlap between the reported susceptibility loci indicates
pleiotropic effects within shared molecular pathways for the
shared skin pathology. However, given the estimated greater
genetic burden for PsA, we hypothesize that PsA-speciﬁc risk loci
exist. As more data on PsA genetics are published, there is an
emerging evidence to support this hypothesis.
A well-established example to support genetic differentiation
involves the associations to genes in the human leukocyte antigen
(HLA) class I region of the major histocompatibility complex
(MHC) on chromosome 6. Studies have demonstrated that
certain alleles of HLA-B confer risk speciﬁcally for PsA
(B*08, B*27,B*38), while HLA-C*06 is speciﬁc for psoriasis10. A
functional polymorphism within the MICA gene (rs1051792)
has also been suggested to be speciﬁc for purely cutaneous
manifestations of psoriasis11. However, given the highly
correlated nature of the two phenotypes and the extensive
linkage disequilibrium (LD) across this region, it is difﬁcult to
conﬁrm any disease-speciﬁc associations within the MHC.
Outside of the MHC, a number of reports have suggested
distinct variants or differences in effect sizes and allele frequencies
between the two traits at a number of loci including IL23R,
TRAF3IP2, FBXL19 and REL12–15. A number of studies have
reported evidence to support the association to the IL13 gene at
chromosome 5q31 as being speciﬁc to PsA16–18. However
subsequent large psoriasis studies, including subtype analysis,
have all reported robust association to IL13 (refs 19,20). It is
worth noting that some of those studies will be confounded by
phenotype misclassiﬁcation due to the presence of unidentiﬁed
PsA patients within the psoriasis study group. To date, conclusive
evidence for PsA-speciﬁc genetic risk factors outside of the HLA
region has yet to emerge.
In this study, we use the Immunochip genotyping array to ﬁne-
map previously reported immune-related susceptibility loci,
including known psoriasis susceptibility loci, to identify novel
PsA susceptibility loci in a collection of samples from 1,962 PsA
patients and 8,923 healthy population controls of Caucasian
ancestry. The study reveals important insights into the genetics of
PsA susceptibility as we ﬁnd evidence for a distinct PsA variant at
the known psoriasis susceptibility locus, IL23R, and we identify a
new PsA-speciﬁc association at chromosome 5q31. Together,
these results begin to highlight the important differences in
susceptibility to PsA and psoriasis.
Results
Statistical quality control. Following quality control (QC), there
remained 129,874 polymorphic single-nucleotide polymorphisms
(SNPs) for analysis in 1,962 case and 8,923 control samples; full
details of sample and SNP exclusions are described in
Supplementary Tables 1 and 2. The genomic inﬂation factor (l)
was estimated to be 1.07 (standardized for an equivalent study of
1,000 cases and 1,000 controls, l1000, the estimate was 1.02),
indicating minimal population stratiﬁcation (quantile–quantile
plots are presented in Supplementary Fig. 1).
Primary association analysis. The PCA-corrected analysis of all
study samples showed association at genome-wide signiﬁcance
(Po5 10 8) at eight loci (Table 1, Supplementary Fig. 2).
Seven of these have previously been reported for psoriasis
(MHC, TRAF3IP2, IL12B, IL23R, IL23A-STAT2, TNIP1, TYK2)
(Table 1). On comparison with the recently reported psoriasis
Immunochip study, we found at least nominal evidence of
association to the 36 previously reported loci (Po0.05; Table 1)
suggesting substantial overlap between the two phenotypes20. In
addition, the effect estimate was similar at loci where the SNP, or
a highly correlated proxy, was associated with both the
phenotypes (Supplementary Fig. 3).
Distinct PsA risk variants at the IL23R locus. We noted that the
PsA study index SNP is not always highly correlated with the
reported psoriasis index SNP; notable examples include IL23R,
TYK2 and NOS2A loci (r2o0.2). This was investigated further by
re-analysing the previously reported psoriasis risk loci in PsA
while including the psoriasis index SNP as a covariate
(Supplementary Table 3). Six loci remained signiﬁcant
(Po1 10 4) following conditional analysis and were further
investigated by comparing model ﬁt using likelihood ratio tests
(LRT). Only one locus, IL23R, demonstrated true independence
of the psoriasis SNP; the PsA-associated SNP rs12044149
remained highly signiﬁcant (P¼ 2.4 10 14) after conditioning
on the psoriasis SNP, rs9988642, and the addition of rs9988642
did not improve the model ﬁt with LRT (P¼ 0.21). Although only
a single effect at the IL23R locus has been reported for psoriasis,
multiple independent risk haplotypes have been reported for
ankylosing spondylitis (AS) tagged by the SNPs rs11209026,
which is highly correlated with rs9988642, and rs11209032
(ref. 21). The PsA index SNP was found to be independent of the
AS second effect and remains highly signiﬁcant after including
rs11209032 as a covariate (P¼ 1.48 10 15). The data provide
compelling evidence for a distinct PsA risk variant at IL23R.
5q31 is a susceptibility locus speciﬁcally for PsA. We selected
index SNPs from two novel loci at chromosome 5q31 and 1q31
and genotyped them in an independent cohort of PsA (n¼ 864),
psoriasis (n¼ 1,054) and control (n¼ 925) samples. In addition,
genotype data were available from the WTCCC psoriasis cohort
consisting of 1,784 psoriasis samples following the exclusion
known PsA samples and 5,175 control samples19. The index SNP
at chromosome 5q31, rs715285, maps to an intergenic region
ﬂanked by the genes CSF2 and P4HA2 and this region has been
reported to be a susceptibility locus for multiple immune-related
diseases including juvenile idiopathic arthritis, inﬂammatory
bowel disease (IBD) and asthma. This association was replicated
in the independent cohort of patients with PsA, and meta-
analysis of PsA cohorts provides convincing evidence of
association with susceptibility to PsA (Pvalidation¼ 4.0 10 4,
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Pmeta¼ 4.38 10 13), and is independent of the previously
reported associations to IL13 (ref. 20; Table 2, Fig. 1).
Interestingly, the SNP reached only nominal signiﬁcance in two
independent psoriasis cohorts (PErlangen¼ 0.05, PWTCCC2¼ 0.21,
Pmeta¼ 0.04). Using multinomial logistic regression, we found
that the effect estimates for rs715285 in PsA and psoriasis (odds
ratio (OR)¼ 1.25 and 0.99, respectively) are signiﬁcantly different
(P¼ 7.05 10 7) providing support that this is a PsA-speciﬁc
risk locus (Table 2).
Each PsA-associated region (index SNPo1.0 10 4) with
sufﬁcient marker density (minimum 100 SNPs) was imputed and
we applied a Bayesian reﬁnement approach to select credible SNP
sets that best explain the observed association (Supplementary
Table 4; ref. 22). In order to further prioritize SNPs with potential
functional effects, the sets were functionally annotated against
gene transcripts and ENCODE features. Consistent with
other reports for complex traits, we ﬁnd that most SNPs map
to intronic and intergenic regions with large proportions
Table 2 | Association statistics for two novel susceptibility loci at chromosome 1q31 and 5q31.
SNP Chr. Position
(bp)
Notable
genes
Risk/non-
risk allele
Stage Sample Phenotype RAF
(case)
RAF
(control)
P-value OR Meta-
analysis
P-value
rs2477077 1 197,671,115 DENND1B T/C Discovery Immunochip PsA 0.26 0.22 1.20E6 1.23 2.36E 7
Validation Erlangen PsA 0.21 0.19 0.07 1.17
Validation Erlangen Psoriasis 0.22 0.19 6.07E 3 1.25 2.40E 7
Validation WTCCC2 Psoriasis 0.25 0.21 2.24E 5 1.21
rs715285 5 131,485,383 CSF2 |
P4HA2
G/A Discovery Immunochip PsA 0.48 0.46 2.654E 10 1.25 4.38E 13
Validation Erlangen PsA 0.49 0.43 4.04E4 1.27
Validation Erlangen Psoriasis 0.46 0.43 0.05 1.14 0.04
Validation WTCCC2 Psoriasis 0.47 0.46 0.21 1.05
bp, base pair; Chr, chromosome; OR, odds ratio; RAF, risk allele frequency.
Table 1 | Association statistics for the 36 previously reported psoriasis susceptibility loci.
SNP Chr. Position (bp) Notable genes Risk/non-risk allele RAF (case) RAF (control) P-value OR Tsoi SNP r2 Tsoi SNP
rs33980500 6 111,913,262 TRAF3IP2 T/C 0.11 0.07 2.65E 16 1.6 rs33980500 1
rs4921482 5 158,764,478 IL12B | ADRA1B T/C 0.74 0.67 1.47E 15 1.4 rs4379175 0.85*
rs12044149 1 67,600,686 IL23R T/G 0.32 0.25 2.25E 15 1.4 rs9988642 0.14
rs2020854 12 56,743,367 STAT2 T/C 0.96 0.93 7.73E 10 1.7 rs2066819 0.99
rs34725611 19 10,477,067 TYK2 A/G 0.76 0.71 2.99E09 1.3 rs34536443 0.09
rs76956521 5 150,464,641 TNIP1 | ANXA6 C/A 0.08 0.05 4.98E09 1.5 rs2233278 1
rs4795067 17 26,106,675 NOS2A G/A 0.39 0.34 1.94E07 1.2 rs28998802 0.06
rs984971 2 163,224,521 IFIH1 T/G 0.68 0.64 3.62E06 1.2 rs17716942 0.3
rs7523412 1 25,294,264 RUNX3 | SYF2 A/G 0.54 0.5 5.42E06 1.2 rs7536201 0.99
rs848 5 131,996,500 IL13 C/A 0.85 0.82 1.05E05 1.2 rs1295685 0.96
rs7552167 1 24,518,643 IL28RA | GRHL3 G/A 0.89 0.86 1.53E05 1.3 rs7552167 1
rs6063454 20 48,590,791 ZNF313 | SNAI1 G/T 0.63 0.59 2.90E05 1.2 rs1056198 0.9
rs1306395 2 61,076,272 PAPOLG | REL T/C 0.61 0.57 2.99E05 1.2 rs62149416 0.77
rs1133071 9 32,455,674 DDX58 C/T 0.34 0.3 3.36E05 1.2 rs11795343 0.18
rs892085 19 10,818,092 ILF3 T/C 0.59 0.55 4.02E05 1.2 rs892085 1
rs2298428 22 21,982,892 LOC150223 T/C 0.2 0.18 4.38E05 1.2 rs4821124 0.96
rs6713082 2 62,516,544 B3GNT2 | TMEM17 A/C 0.27 0.24 4.59E05 1.2 rs10865331 0.29
rs8016947 14 35,832,666 PSMA6 | LOC122589 G/T 0.6 0.56 9.65E05 1.2 rs8016947 1
rs4796659 17 40,590,029 PTRF | ATP6V0A1 G/T 0.93 0.91 0.000132 1.3 rs963986 0.01
rs62376445 5 96,196,721 ERAP1 | ERAP2 C/A 0.96 0.94 0.000174 1.4 rs27432 0.02
rs610604 6 138,199,417 TNFAIP3 G/T 0.35 0.32 0.000325 1.1 rs582757 0.78
rs7761186 6 512,951 EXOC2 | LOC727827 T/C 0.99 0.98 0.000709 1.8 rs9504361 0.01
rs645078 11 64,135,298 RPS6KA4 A/C 0.64 0.61 0.00086 1.1 rs645078 1
rs11121129 1 826,8095 ERRFI1 | SLC45A1 A/G 0.33 0.3 0.000934 1.1 rs11121129 1
rs4936059 11 128,502,496 ETS1 | FLI1 G/A 0.35 0.32 0.001475 1.1 rs3802826 0
rs12928822 16 11,403,893 PRM1 | C16orf75 C/T 0.84 0.81 0.001593 1.2 rs367569 0.56
rs6693105 1 152,590,663 LCE3B | LCE3A C/T 0.68 0.65 0.002892 1.1 rs6677595 1
rs7197717 16 31,083,075 ZNF668 C/A 0.41 0.38 0.003544 1.1 rs12445568 0.92
rs4561177 11 109,962,432 LOC260340 | ZC3H12C A/G 0.6 0.57 0.003782 1.1 rs4561177 1
rs73112675 7 37,379,030 ELMO1 G/A 0.2 0.17 0.004116 1.1 rs2700987 0.18
rs602422 18 51,805,130 POLI C/T 0.31 0.29 0.004767 1.1 rs545979 1
rs1972346 10 81,067,480 ZMIZ1 C/G 0.61 0.59 0.008258 1.1 rs1250546 0.4
rs11652075 17 78,178,893 CARD14 C/T 0.51 0.49 0.01423 1.1 rs11652075 1
rs1973919 6 159,440,727 RSPH3 | TAGAP C/T 0.33 0.31 0.01812 1.1 rs2451258 0.22
rs12236285 9 110,855,243 LOC392382 A/G 0.08 0.07 0.03838 1.2 rs10979182 0.03
bp, base pair; Chr, chromosome; OR, odds ratio; RAF, risk allele frequency.
*Tsoi secondary effect.
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mapping to elements predictive of transcriptional regulation
(Supplementary Table 5). Focusing speciﬁcally on the putative
PsA-speciﬁc locus at chromosome 5q31, we observe that 99% of
the posterior probability for the association rests on a credible
SNP set consisting of 35 SNPs from a total of 1,644 following
imputation. The credible SNP set deﬁnes a 137 kb region
(chr5:131,418,948–131,556,203) partially spanning the P4HA2
gene (Supplementary Fig. 4). The functional annotation shows
that most SNPS are intronic within the P4HA2 gene or intergenic
mapping to ENCODE features indicative of transcriptional
activity, such as DNase hypersensitivity sites and histone
modiﬁcation marks (H3K4Me1). Four SNPs map to multiple
ENCODE features (rs10065787, rs3846728, rs27437 and
rs7721882), but of particular interest is the SNP, rs10065787,
which maps to a site of multiple clusters for occupancy of
transcription factors known to be important for CD8þ T-cell
differentiation including, RUNX3, BATF and IKZF1 (refs 23,24).
To help prioritize candidate genes in this gene-rich region, we
performed cell-speciﬁc expression quantitative trait loci (eQTL)
analysis in primary cells for CD8þ and CD4þ T cells from
healthy individuals. The most signiﬁcant correlation between
gene expression and genotype was with rs11955347 and probes in
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Figure 1 | Regional association plots for chromosome 5q31 for PsA (cases¼ 1,962, controls¼8,923) and psoriasis (cases¼ 1,784, controls¼ 5,175).
Circles represent  log10(P value) from logistic regression for imputed SNPs, colour of the circle represents linkage disequilibrium (r2) with the index SNP
(purple circle). Top panel, imputed Immunochip data; middle panel, imputed Immunochip data conditioned on the index SNP rs715285; bottom panel,
imputed WTCCC2 GWAS data for psoriasis, excluding known PsA samples.
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the SLC22A5 in CD8þ T cells and CD4þ T cells (Fig. 2). This
SNP is highly correlated (r2¼ 0.7) with the index SNP, rs715285
(Fig. 2), where the risk allele, G, of rs715285 is in phase with the A
allele of rs11955347, which in turn corresponds with decreased
expression of SLC22A5.
1q31 is a novel psoriasis susceptibility locus. The index SNP at
chromosome 1q31 (rs2477077) is located within intron 3 of the
gene DENND1B (transcript variants 2 and 3). This gene has
previously been reported to be associated with susceptibility to
IBD and primary biliary cirrhosis (PBC). Our reported index SNP
is highly correlated with both variants (rs2488389, r240.99 and
rs2488393, r2¼ 0.94, respectively)25,26. Validation of this SNP in
an independent cohort of patients with PsA did not reach
statistical signiﬁcance (P¼ 0.07). However, there was evidence to
support association to this SNP in both psoriasis data sets, further
substantiated by meta-analysis (PErlangen¼ 6.07 10 3,
PWTCCC2¼ 2.24 10 5, Pmeta¼ 2.40 10 7; Table 2). Meta-
analysis of all psoriasis and PsA data from Immunochip and
combined validation data sets exceeded genome-wide signiﬁcance
(P¼ 3.05 10 8; Supplementary Fig. 5). The results suggest that
DENND1B is a susceptibility locus for psoriasis per se.
Independent effects at three non-HLA loci. To identify inde-
pendent secondary effects at the PsA loci, forward stepwise
logistic regression was performed where the index SNP was
included as a covariate. We found evidence (Po10 4) of sec-
ondary effects at three loci; IFIH1, IL12B and NOS2
(Supplementary Table 6).
CD8þ memory primary cells are critical for PsA. We next
attempted to identify the relevant cell types for PsA by testing the
overlap of associated variants with markers of transcriptional
activity. Here, we tested 20 associated SNPs (Po1.0 10 4 for
previously associated loci and validated novel loci) for overlap
with trimethylation of histone H3 at lysine 4 (H3K4me3) peaks in
34 cell and tissues types. This method has previously been
demonstrated to be effective at identifying relevant cell types for
multiple complex traits27. The most signiﬁcant association was to
CD8þ memory primary cells (P¼ 1.6 10 3) with four SNPs
showing a speciﬁcity greater than the permuted 95th percentile
(0.26) (Supplementary Table 7). It is interesting to note that the
SNP (rs10065787) with the highest speciﬁcity for CD8þ memory
primary cells is one of the four SNPs prioritized by functional
annotation from the PsA-speciﬁc locus at chromosome 5q31
(SNP score¼ 0.86) (Supplementary Table 8).
Independent associations to three HLA genes. The high quality
imputed variants for the HLA region consisted of 70 classical
HLA alleles at two-digit resolution, 88 HLA alleles at four-digit
resolution, 335 amino acid positions and 6,830 SNPs for the
subset of UK samples (cases¼ 1,464, controls¼ 8,469). The
strongest association from the initial analysis of all imputed
markers was to the classical four-digit allele of HLA-C*0602
(P¼ 5.85 10 52, OR¼ 2.36; Table 3, Fig. 3). After adjusting for
the effect of HLA-C*0602, no secondary effects were found that
were independent of HLA-B. We conclude that there are no
secondary effects at HLA-C after adjusting for HLA-C*0602 in
this data set and the second major effect is to HLA-B. We next
conditioned on all HLA-C two- and four-digit alleles and found
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Figure 2 | eQTL for SLC22A5 in CD4þ (left) and CD8þ T cells (right). Log gene expression of SLC22A5 grouped by genotype of rs11955347 (n¼ 22).
Linkage disequilibrium of this SNP with the index SNP, rs715285, is r2¼0.7. P-value from linear regression of gene expression and genotype. The risk allele
of rs715285 corresponds with decreased expression of SLC22A5.
Table 3 | Three independent associations to HLA class I genes in the UK Immunochip data set.
Gene Position Allele/residue Omnibus P value A1/A2 P-value* Minor allele freq. Odds ratio* CI*
Cases Controls
HLA-C — *0602 5.85 10 52 P/A — 0.19 0.09 2.34 2.02:2.71
HLA-B 67 Cysteine 5.6 10 13 P/A 6.53 10 14 0.15 0.12 1.62 1.43:1.84
Phenylalanine P/A 7.44 106 0.23 0.25 1.29 1.15:1.44
Methionine P/A 7.89 10 5 0.1 0.05 1.45 1.20:1.72
Tyrosine P/A 0.79 0.13 0.17 1.02 0.89:1.26
Serine P/A ref 0.39 0.42 ref ref
HLA-A — *0201 3.31 10 13 P/A — 0.34 0.28 1.39 1.27:1.52
A, absent; A1, allele 1; A2, allele 2; CI, conﬁdence interval; freq, frequency; HLA, human leukocyte antigen; P, present.
*Calculated in a regression including HLA-C*0602, HLA-B amino acid position 67 and HLA-A*0201.
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the strongest association to an amino acid at position 67 within
HLA-B (P¼ 1.89 10 12) where the presence of a cysteine
conferred the greatest increased risk (OR¼ 2.85; Fig. 3, Table 3
and Supplementary Fig. 6) and deﬁnes the classical HLA-B*27
allele. This is consistent with ﬁndings reported in a previous study
by Okada et al.28
Proceeding with a forward stepwise logistic regression to
identify markers outside HLA-C and HLA-B, by including all
HLA-C and HLA-B two- and four-digit alleles in the model, we
ﬁnd the next most statistically signiﬁcant variant was to the four-
digit allele HLA-A*0201(P¼ 3.31 10 13; Fig. 3). The effect at
HLA-A*0201 could not be differentiated from that of four highly
associated amino acids at positions 62, 74, 95 and 107
(Supplementary Fig. 6). No further variants reached the
predeﬁned level of signiﬁcance following adjustment for HLA-
C, HLA-B and HLA-A*0201.
We validated this association proﬁle in an independent data set
of 572 PsA cases and 888 controls from Germany and replicated
the associations to HLA-C*0602 (P¼ 1.59 10 14) and the
amino acid at position 67 of HLA-B (P¼ 1.89 10 12;
Supplementary Table 9 and Supplementary Fig. 7; ref. 13)
The association to HLA-A was also replicated with the presence
of glycine at position 107 conferring risk (P¼ 3.3 10 9)
(Supplementary Fig. 7). This residue deﬁnes the classical allele
four-digit allele HLA-A*0201 identiﬁed in the UK analysis and the
two variants are highly correlated (r2¼ 0.94).
Discussion
This study demonstrates substantial allele sharing at previously
reported psoriasis susceptibility loci as would be expected given
the shared clinical characteristics. In addition, the study reveals
key insights into the genetics of PsA that begin to explain
fundamental differences between psoriasis and PsA. We identify a
PsA-speciﬁc risk locus at chromosome 5q31, distinct risk variants
for PsA at a known psoriasis susceptibility locus and provide a
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Figure 3 | Association plots for three independent associations to HLA Class I genes. Analysis was performed in 1,464 cases and 8,469 controls from
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further line of evidence to support CD8þ T cells as a relevant cell
type for pursuing functional experiments. In addition, we identify
a novel risk locus for susceptibility to psoriasis per se at
chromosome 1q31 to a variant in DENND1B. Finally, we report
results for the imputation of HLA classical alleles and amino acids
identifying three independent effects to MHC class I molecules.
The results provide compelling evidence for the existence of PsA-
speciﬁc risk loci that we would expect to ﬁnd given the increased
genetic burden estimated from family studies.
The PsA-speciﬁc association on chromosome 5q31 forms part
of a large region containing many functionally interesting
candidate genes. There is extensive LD across this region and it
is challenging to statistically differentiate a causal SNP. However,
with the integration of eQTL and ENCODE data, we were able to
prioritize a single candidate gene (SLC22A5) and candidate SNP
(rs10065787) for further investigation. The SLC22A5 gene
encodes a transmembrane cation transporter found in a wide
variety of tissues and organs. It has a functional role in
ergothioneine and carnitine transport in addition to control of
intestinal absorption. This last point is of particular interest in the
context of gut inﬂammation/microbiome. Given the overlap of
Crohn’s disease with psoriasis and PsA, there is growing interest
in the possibility that PsA may be triggered by gut microbes in
genetically susceptible individuals. SLC22A5 has previously been
reported to be associated with IBD25, whereas previous psoriasis
reports relating to chromosome 5q31 have focused on variants
mapping to the IL13 gene. The index SNP in this PsA study is
statistically independent of the IL13 psoriasis-associated variant.
It should be noted that while the eQTL analysis and ENCODE
annotation presented in this study are informative with regards to
prioritizing SNPs and candidate genes for functional validation in
the laboratory, the current data sets may not represent the true
biological context. For example, eQTLs in immune cells are
known to be inﬂuenced by stimulation with many eQTLs only
observed under stimulated conditions29.
Distinct PsA SNPs have previously been reported at known
psoriasis susceptibility loci12; here we conﬁrm that the PsA risk
variant at the IL23R locus is independent from the reported
psoriasis variant (Pcond¼ 2.4 10 14) and including the
reported psoriasis SNP does not improve the ﬁt of the model
(PLRT¼ 0.21). However, we do not ﬁnd evidence to support a
distinct variant at the TNFAIP3 locus as reported by Nair et al., as
our most associated SNP variant is highly correlated with
reported psoriasis Immunochip variant (r2¼ 0.78).
Identifying disease-speciﬁc genetic risk factors has important
implications for epidemiology and pharmacogenetics as it may
allow the stratiﬁcation of patients with psoriasis to identify those
at high risk of developing PsA and potentially identify new
therapeutic targets. Indeed some therapies used in the treatment
of psoriasis, such as Ciclosporin and Fumaderm, do not work in
the treatment of PsA; whereas others such as Sulfasalazine and
Leﬂunomide, effective for PsA, have no or limited effect in
psoriasis. There is also data to show that biological agents
including antitumour necrosis factor a and Interleukins 12/23
inhibitors are effective in the treatment of both psoriasis and PsA;
yet, not all patients respond predictably, an effect potentially
driven in part by differing genetic factors between the two
conditions.
Although the results presented here provide evidence for the
existence of PsA-speciﬁc risk loci, the study design is not ideal for
the detection of such loci. Future study design would involve a
cross-phenotype analysis comprising large numbers of PsA cases,
cutaneous only psoriasis (PsC) cases and healthy controls. This
would allow a direct comparison of effects between the two
phenotypes to assess pleiotropy. Power is a key issue, as in all
genetic studies, and phenotype misclassiﬁcation may inﬂuence
power. The presence of unidentiﬁed PsA in the PsC comparison
group will reduce power requiring robust phenotyping of the PsC
cohort, for example, by restricting the analysis to psoriasis
patients with 10 years of disease without a diagnosis of PsA. We
have attempted to address the problem in the current study by
excluding known PsA samples from the WTCCC2 collection on
the basis of the information from contributors of the samples. In
addition, the Erlangen psoriasis cohort speciﬁcally recruits
patients with a disease duration of 10 years or more without a
diagnosis of PsA. A number of previous psoriasis GWAS have
directly compared genotypes between PsC and PsA14,30; for
example, Nair et al. found modestly signiﬁcant frequency
differences between PsC and PsA for SNPs at the HLA-C
(P¼ 0.006) and IL12B (P¼ 0.01) loci31. However, these studies
have focused only on conﬁrming the association of known and
newly discovered psoriasis susceptibility loci in PsA as opposed to
discovering novel PsA-speciﬁc loci.
Here we provide empirical evidence that PsA genetic risk
variants co-localize with epigenetic markers of open chromatin
preferentially in CD8þ memory cells. Thus, we add a further line
of evidence to support their importance in the underlying disease
mechanism and as a relevant cell type for pursuing functional
studies. CD8þ T cells have been postulated as having a key role
in the development of PsA based on several lines of evidence32.
First, immunohistochemistry and ﬂow cytometry experiments
have found that CD8þ T cells predominate in the synovial ﬂuid
of patients with PsA compared with peripheral blood33. In
addition, levels of these IL-17 producing CD8þ T cells correlate
with clinical measures of disease activity and are increased in
patients with erosive disease34. Second, the importance of CD8þ
cells is underlined by genetic evidence; the strongest genetic
associations with susceptibility to PsA are to alleles of HLA genes
in the MHC class I region. Molecules encoded by these genes are
responsible for the presentation of peptides to the T-cell receptor
of CD8þ lineage T cells10,35. Outside the MHC region,
associations to key genes involved in the differentiation of
CD8þ cells, such as RUNX3, have been found to PsA36. The
susceptibility variant at this locus is highly correlated with the
reported AS SNP (rs6600247, r2¼ 0.97) and variants at this locus
have been shown to be associated with CD8þ T-cell counts21.
Only four of the 20 SNPs included in our analysis were found to
have high scores for CD8þ memory T cells, potentially
highlighting the sensitivity of this method with low numbers of
markers. Conclusions regarding critical cell types will become
more robust as more loci are discovered.
The differentiation of CD8þ T cells is regulated by a number
of transcription factors including BATF and RUNX3, which were
identiﬁed during the bioinformatic analysis of 5q31 as a potential
mechanism for the observed eQTL. It is also interesting to note
that the 5q31 index SNP had the strongest individual SNP
speciﬁcity score for CD8þ memory T cells. BATF4 has been
shown to epigenetically regulate the differentiation of CD8þ cells
via histone acetylation37. While in this study we focused on
H3K4me3, a marker of active promoters, the chromatin marks
often co-localize and there is, indeed, a H3K27Ac peak in close
proximity to the index SNP. Further investigation will require
genome-wide binding proﬁles of these transcription factors in
CD8þ memory T cells, which in turn may reﬁne candidate loci.
The DENND1B locus has previously been associated with IBD
(rs2488389), PBC (rs2488393) and childhood asthma (rs2786098;
refs 25,26,38). Our reported SNP, rs2477077, is highly correlated
with both the IBD and PBC reported variants (r240.94) with
directionally consistent effect estimates. However, very little
correlation is observed with the asthma reported SNP (r2o0.08).
This implies a pleiotropic locus containing both shared and
distinct causal variants for different phenotypes39 where the
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psoriasis, IBD and PBC SNPs likely tag the same causal variant,
but with an independent causal variant for asthma. The function
of DENND1B is not fully understood, but it has been found to be
upregulated in T cells providing support for the relevance of this
type of cell in PsA and psoriasis aetiology. The data from our
study suggest that this is a susceptibility locus for psoriasis
irrespective of the presence of inﬂammatory arthritis.
We identiﬁed and validated three independent effects to MHC
class I genes, with main effects to the imputed four-digit allele
HLA-C*0602, amino acid at position 67 of HLA-B and HLA-
A*0201. These associations to the three different genes were
replicated in an independent data set; however, the differing
primary associations at the HLA-A locus between the discovery
and validation cohorts highlight the challenges in identifying the
true causal variant in a region of high LD. The variants identiﬁed at
HLA-A for both data sets are highly correlated and considered to
tag the same effect. The associations to these loci have previously
been reported for psoriasis and, consistent with previous studies,
we ﬁnd the effect estimate at HLA-C*0602 to be lower for PsA than
that reported for psoriasis, with OR of 2.34 and 3.26, respectively28.
The effect estimate and direction at HLA-B and HLA-A are similar
to that reported for psoriasis. Associations to HLA-B*27 and HLA-
A*0201 have previously been reported to AS21, providing further
support of genetic overlap between these two conditions. The
direction of effect in PsA at these loci is the same as AS, but the
magnitude of effect at HLA-B*27 is substantially lower for PsA
(OR¼ 46 and OR¼ 1.90, respectively).
Associations to HLA-B have previously been reported to anti-
citrullinated-protein-autoantibody-negative (ACPA ) rheuma-
toid arthritis (RA) where an aspartate at position 9 has been
reported to increase the risk40. However, no associations were
observed to this amino acid (P¼ 0.88) or the related HLA-B*08
allele (P¼ 0.49) in our PsA samples. Furthermore, no convincing
evidence for association was observed for the other reported
ACPA RA association to HLA_DRB1*03 (P¼ 0.36, amino acid
position 11; P¼ 0.02).
PsA is a clinically heterogeneous disease and it has been shown
that certain clinical sub-phenotypes correlate with particular HLA
alleles, for example HLA-B*27 has been shown to be associated
with the extent and severity of axial involvement41. Future studies
would greatly beneﬁt from the incorporation of clinical
information to help resolve the true nature of associations
across this region39. This heterogeneity will also confound the
naive comparison of results across cohorts where the relative
proportions of clinical subtypes may differ.
In summary, this study identiﬁes key insights into the genetics
of PsA that begin to explain fundamental differences between
psoriasis and PsA. We identify a PsA-speciﬁc risk locus at
chromosome 5q31 where functional annotation and cell-speciﬁc
gene expression data identify putative candidate SNP
(rs100657871) and gene (SLC22A5) that can be prioritized for
functional evaluation. In addition, the study demonstrates the
existence of distinct risk variants at a known susceptibility locus
(IL23R) and provides a further line of evidence to support CD8þ
T cells as a relevant cell type for pursuing functional experiments.
We identify a novel risk locus for susceptibility to psoriasis per se
at chromosome 1q31 to variant in DENND1B. Finally, we report
results for the imputation of HLA classical alleles and amino acids
identifying three independent effects to MHC class I molecules.
The results provide compelling evidence for the existence of PsA-
speciﬁc risk loci, which is not unexpected, given the increased
genetic burden estimated from family studies.
Methods
Genotyping. Samples were genotyped using Immunochip, an Illumina iSelect HD
custom genotyping array, in accordance to the manufacturer’s instructions at ﬁve
genotyping centres: the Wellcome Trust Sanger Institute, the Centre for Public
Health Genomics at The University of Virginia, Arthritis Research UK Centre for
Genetics and Genomics at The University of Manchester, the University of
Queenland Diamantina Institute, and the Institute of Molecular Medicine at The
University of Dublin.
Genotype calling and quality control. All case and control idat ﬁles were collated
at the Arthritis Research UK Centre for Genetics and Genomics laboratory at The
University of Manchester. Genotype clustering and calling was performed using the
GenomeStudio Data Analysis software platform (Genotyping Module v1.8.4) as a
single project using the Illumina manifest ﬁle Immuno_BeadChip_11419691_
B.bpm (NCBI Build 36, hg18). Preliminary genotype clustering was performed
using the default Illumina cluster ﬁle Immunochip_Gentrain_June2010.egt to
identify poor quality sample (call rateo0.90). Following exclusion of these samples,
automated reclustering was performed to calibrate cluster on the basis of the study
samples. An extensive manual review of genotype clusters was performed on the
basis of ranking of the quality metrics; cluster separation (o0.4), signal intensity
(o1.0), call rate (o0.98) and allele frequency. SNPs with a cluster separationo0.4
and a call rate o0.95 were non-polymorphic, duplicates or mapping to
chromosome Y or the mitochondria were excluded before further sample QC.
Statistical quality control. Samples were excluded with a call rateo0.98 or if they
were identiﬁed as being an outlier on the basis of autosomal heterozygosity (3 s.d.
from the mean autosomal heterozygosity of samples passing the call rate threshold).
Duplicate and related individuals were identiﬁed using identity-by-descent, per-
formed in PLINK using a set of 18,664 LD pruned (r2) SNPs with a minor allele
frequency (MAF) 40.05. For each pair of individuals with a PI_HAT 40.2, the
sample with the lowest call rate was excluded. Principal component analysis (PCA),
using EIGENSOFT (v4.2) and the LD pruned SNP set, was performed to infer
ancestry (Supplementary Fig. 8). Outliers of the main cluster were identiﬁed using a
nearest-neighbour clustering algorithm based on the ﬁrst two principal components
(performed using the R package nnclust (version 2.2)). A ﬁnal round of SNP ﬁltering
was performed on the remaining high quality samples; this included a call rate
threshold ofZ0.98 in cases and controls, exclusion of SNPs with signiﬁcant deviation
from Hardy–Weinberg equilibrium o5 10 7 in controls, and a MAF o0.01.
Association testing. Case–control association testing was performed using
logistic regression including the top two principal components as covariates in
PLINK (v1.07). Principal components were generated for all the samples passing
QC, as described above. Cluster plots for all reported SNPs were manually checked
and poor-performing SNPs were removed. At selected loci, effects independent of
the index SNPs were determined by forward stepwise logistic regression including
the index SNP as a covariate. Genomic inﬂation was calculated using a set of 2,840
SNPs passing QC that were included as part of either a reading and writing or
psychosis and schizophrenia study. SNPs mapping to previously reported psoriasis
susceptibility loci were excluded to create a null set of SNPs to estimate the overall
inﬂation of test statistics using genomic control using the R package gap (version
1.1–10).
Conditional analysis. We performed conditional analysis using LRT to determine
which model represented the best ﬁt. The aim was to test if adding additional
genetic markers (alternative model), such as known psoriasis SNPS, signiﬁcantly
improved the models ﬁt for phenotypic variance over the original null model. A
signiﬁcant LRT P value indicates that the alternative model explains a greater
proportion of the phenotypic variation and all markers in the model are relevant to
disease. The Akaike information criterion and the Bayesian information criterion
were used to assess model ﬁtness where a decrease in either is suggestive of
improved ﬁtness with minimal parameters.
In the case of previously described susceptibility loci we include the reported
psoriasis SNP, or multiple SNPs where independent effects have been observed, as
covariates in the regression model. We interpret a situation where the PsA SNP
remains signiﬁcant after conditioning on known psoriasis SNPs and where adding
the known psoriasis SNP to the model does not signiﬁcantly improve the ﬁt as
evidence to support a distinct variant for PsA.
Multinomial logistic regression. To test if the effect estimates for rs715285 were
signiﬁcantly different between PsA and psoriasis, we performed a multinomial
logistic regression (Stata version 13) including the ﬁrst two principal components
as covariates. The genotype data for rs715285 from WTCCC psoriasis samples
(n¼ 1,784 following exclusion of known PsA samples) was combined with the
PsA immunochip data. The genotyping rate in the combined data set for rs715285
was 499.9%.
Validation of novel loci. The index SNP for each novel locus passing 5.0 10 6
was selected for validation genotyping in independent cohorts of 864 PsA cases,
1,054 psoriasis cases and 925 healthy control samples by the University of Erlan-
gen. Meta-analysis of the German and Immunochip PsA summary statistics was
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performed using PLINK (v1.07) using inverse variance and assuming a ﬁxed effect
across the two populations. In addition, we explored these associations in the
WTCCC2 GWAS psoriasis data set, after excluding known PsA patients (n¼ 394)
providing a data set of 1,784 psoriasis patients and 5,175 controls19. Meta-analysis
of the German and WTCCC2 psoriasis summary statistics was based on P values
weighted for study sample size performed in R using the gap package. An overall
analysis was performed by meta-analysis of the combined Erlangen data and
Immunochip data to test for association to psoriasis per se. The WTCCC2 data set
was not included in this analysis because of large overlap in control samples.
Fine mapping. Selected loci were phased and imputed using the PsA Immunochip
data set and, for the 5q31 locus, the WTCCC2 psoriasis data set. Phasing was
performed with SHAPEIT2 (v2) and imputation was performed with Impute2
(v2.3) using the 1000 Genomes integrated variant data set version 3 as the reference
panel. Post-imputation analysis was restricted to SNPs with an information score
Z0.9 in addition to SNP QC deﬁned above and performed using SNPTEST (v2.5).
For each locus, we applied a Bayesian reﬁnement approach to deﬁne the subset of
SNPs that, based on posterior probability, is 99% likely to contain the causal
disease-associated SNP22 (https://github.com/chr1swallace/ﬁnemap-psa). These
credible SNP sets were then annotated for putative function based on transcript
location (refseq gene annotation) and localization to ENCODE features
(H3K4Me1, H3K4Me3, H3K27Ac, DNase I hypersensitivity and transcription
factor ChIP-Seq clusters) using Annovar42.
PBMC puriﬁcation and genotyping. Twenty-three healthy volunteers were
recruited at the University of Manchester as part of the National Repository
Healthy Volunteers (NRHV) study. All the samples were collected with ethical
committee approval (MREC 99/8/84) and all individuals provided informed con-
sent. The median age of the subjects was 50.5 years (range¼ 26–82 years) with
eight males and 15 females. A total of 20ml peripheral blood was collected in
Vacutainer plus tubes containing EDTA (Becton Dickinson). PBMCs were
extracted within 2 h of collection from 20ml of whole blood using Ficoll Plus
density gradient centrifugation (GE Healthcare). Cells were washed twice with
MACS running buffer (phosphate-buffered saline (PBS), bovine serum albumin,
EDTA and sodium azide; Miltenyi) and total PBMCs counted using the CASY cell
counter (Roche). To allow collection of all the samples, PBMC samples were
immediately cryopreserved in 1ml recovery cell-freezing medium (Gibco) per
5 106 cells at a cooling rate of  1 C per minute. Samples were genotyped using
the Illumina HumanCoreExome v1.0 array, in accordance with the manufacturer’s
instructions. Genotype clustering and calling was performed using the GenomeS-
tudio Data Analysis software platform using the Illumina HumanCoreExome-24
v1.0 Manifest File.
CD4þ and CD8þ cells separation. Automated magnetic activated cell separation
methods were used to positively separate CD4þ and CD8þ T lymphocytes from
thawed PBMCs, as per manufacturer’s instructions (Miltenyi). Typical yields of
CD4þ lymphocytes obtained were between 9.5 105 and 2.69 106 cells; whereas
typical yields of CD8þ lymphocytes were between 4.7 105 and 2.7 106 cells. Cell
population purities were then assessed using a Cyan ADP ﬂow cytometer (Becton
Dickinson) with samples containing on average 95.31% CD3þCD4þ cells
(range¼ 90.21–98.78%) and 99.4% CD8þ cells (range¼ 94.8–100%). All the sam-
ples were immediately suspended in 1ml Trizol reagent (Gibco) for RNA extraction.
RNA extraction and whole transcriptome gene expression. Total RNA was
extracted from CD4þ and CD8þ lymphocytes using Trizol reagent (Gibco) and
1-Bromo-3-chloropropane (BCP) (Sigma Aldrich) in 2ml heavy phase lock gel
tubes (5 prime), according to manufacturer’s instructions. To reduce the risk of
genomic DNA contamination, a DNase treatment was performed using DNase I
(Invitrogen) and acid phenol chloroform (Sigma Aldrich). Sample quality control
was performed using the Nanodrop N1000 (Fisher scientiﬁc) and Bioanalyzer 2100
(Agilent). RNA ampliﬁcation of 400 ng total RNA was performed using the Illu-
mina TotalPrep Ampliﬁcation Kit (Ambion), according to manufacturer’s
instructions. Biotin-labelled cRNAs were then hybridized to the HumanHT-12 v4
Expression (Illumina), according to manufacturer’s instructions.
Cell-speciﬁc eQTL. GenomeStudio (Illumina) software was used to assess control
probe summary statistics and summarize bead level data. Quality control and
differential analysis of summary data was performed using the limma (linear
models for microarray data) bioconductor package. Data were quantile normalized
and subject to log2 transformation Potential batch effects were assessed by visual
inspection of MDS plots and PCA analysis.
Within the 5q31 region, expression data for 18 probes and genotype data for
104 SNPs across 22 CD8þ and 22 CD4þ samples were available. Gene expression
was correlated with genotype with the use of PLINK software (version 1.07), where
association testing was carried out between the genotype data and the expression
data for each probe represented in the region. This was performed separately for
the CD8þ and the CD4þ data sets.
HLA imputation. The snp2hla (v1.0) software package (http://www.broadin-
stitute.org/mpg/epigwas/) was used to impute classical HLA alleles, amino acids
and SNPs within the HLA region (chr6:29-34, hg19) using a reference panel of
5,225 T1DGC samples43. Analysis was performed in the UK subset of samples
using best-guess genotypes from variants passing the QC thresholds: information
score Z0.9, MAF Z0.01 and signiﬁcant deviation from Hardy–Weinberg
equilibrium in controls 41.0 10 3.
Analysis of all markers was performed using logistic regression assuming an
additive effect based on the carriage of alleles. Given that HLA region has been
demonstrated to show geographic variability across the UK44, the logistic
regression was performed with the inclusion of the ﬁrst two principal components,
derived from the UK study sample set, as covariates. For multi-allelic sites, such as
amino acids, we identiﬁed the most common residue or allele in the control
population, which was selected as the reference and excluded from the model. The
P value for each marker was derived from an omnibus test performed with a log-
likelihood ratio test of the null and ﬁtted models. In the ﬁrst instance, the null
model is comprised solely of the ﬁrst two principal components and the ﬁtted
model includes the marker to be tested45,46. To identify independent effects, we
performed a forward stepwise logistic regression where the top marker, ranked by
the log-likelihood P value, was included as a covariate by addition to the null
model. This was repeated until no further marker reached a predeﬁned signiﬁcance
threshold of 6.8 10 6, which is a Bonferroni corrected type I error rate based on
the analysis of 7,323 markers. In addition, variants were only considered to be
independent if they were signiﬁcantly associated in all the previous iterations of the
stepwise logistic regression. To account for all the effect at a particular HLA gene,
we included all two- and four-digit alleles as covariates in the regression model.
Effect estimates were calculated by performing a logistic regression including the
ﬁrst two principal components and the markers identiﬁed in the stepwise
regression as covariates28. Validation was performed with imputation from existing
GWAS data of an independent cohort of 572 cases and 888 controls from the
German population13.
Phenotypic cell type speciﬁcity. The epigwas software package (http://
www.broadinstitute.org/mpg/epigwas/) was used to identify the most phenotypi-
cally related cell type27. All PsA-associated non-HLA SNPs (Po1.0 10 4) were
used in the analysis, which involves the colocalisation of trait-associated SNPs to
the epigenetic chromatin mark H3K4me3 (trimethylation of histone H3 at lysine 4)
in 34 cell and tissue types. The underlying hypothesis is that variants of a particular
phenotype modify gene expression regulatory elements in a cell type relevant to
that phenotype. In turn, these variants should overlap chromatin marks within that
cell type.
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